Related Experiment Video
Updated: Jun 4, 2025
Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
International Multicenter Cohort Study on Beta-Blocker-Free Treatment Strategies for Catecholaminergic Polymorphic
Raquel Neves1, Sahej Bains2, J Martijn Bos3
1Department of Molecular Pharmacology & Experimental Therapeutics (Windland Smith Rice Sudden Death Genomics Laboratory), Mayo Clinic, Rochester, Minnesota, USA.
Insights
For patients with catecholaminergic polymorphic ventricular tachycardia (CPVT) experiencing beta-blocker (BB) side effects, safe and effective BB-free strategies exist. Careful risk assessment allows for tailored BB-free treatment configurations in 10% of CPVT patients.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, life-threatening genetic heart condition.
- Nonselective beta-blockers (BBs) are standard for managing CPVT, but some patients experience adverse effects.
- Alternative treatment strategies are needed for patients intolerant to BBs.
Purpose of the Study:
- To review BB-free treatment options and outcomes in CPVT patients.
- To analyze data from the International CPVT Registry for BB-free strategies.
- To identify effective BB-free configurations for CPVT management.
Main Methods:
- Inclusion of RYR2 variant-positive CPVT patients on BB-free treatment for ≥6 months from the International CPVT Registry.
- Categorization into two groups: intentional nontherapy (INT) for very low-risk patients and alternative strategies for BB-intolerant patients.
- Analysis of treatment strategies including flecainide monotherapy and left cardiac sympathetic denervation.
Main Results:
- 10% of 1,017 CPVT patients (100 individuals) utilized a BB-free strategy.
- 73 patients were in the INT group, primarily asymptomatic low-risk individuals.
- 27 patients received alternative BB-free strategies (flecainide, sympathetic denervation, or both), with only 2 events during a 6-year median follow-up.
Conclusions:
- While BBs are primary for CPVT, 10% of patients require BB-free approaches.
- Careful risk stratification enables the development of safe and effective BB-free treatment plans.
- BB-free strategies offer a viable alternative for select CPVT patients.
Background:
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare, potentially life-threatening genetic heart disease. Nonselective beta-blockers (BBs) are highly effective in reducing CPVT-triggered arrhythmic events. However, some patients suffer from unacceptable BB side effects and might require strategies without a BB.
Objectives:
This study sought to review the spectrum of and outcomes associated with BB-free treatment configurations in patients with CPVT enrolled in the International CPVT Registry.
Methods:
From the Registry, patients with RYR2 variant-positive CPVT treated with a BB-free strategy for ≥6 months were included. Two treatment groups were defined: patients classified as very low risk and treated with intentional nontherapy (INT) and patients who needed to be treated but did not tolerate BBs and were treated with 3 different strategies.
Results:
Overall, 100 of 1,017 patients (10%) were on a BB-free treatment strategy. There were 73 patients (33 females [42%]) in the INT group. In patients 66 (90%), INT was pursued after low-risk assessment in asymptomatic patients and absent or negligible stress test phenotype. Twenty-seven patients (22 females, 81%) were treated using 3 different BB-free treatment strategies (flecainide monotherapy, n = 21; left cardiac sympathetic denervation monotherapy, n = 2; flecainide + left cardiac sympathetic denervation, n = 4). In total, 25 patients (93%) were previously treated with BBs. During a median follow-up of 6 years (IQR: 3-9 years), 2 patients (2%) had a CPVT-associated event.
Conclusions:
Although nonselective BBs remain the cornerstone treatment for CPVT, 10% of patients with CPVT required a BB-free treatment strategy. After careful risk assessment, safe and effective BB-free treatment strategies can be configured.
More Related Videos
Related Concept Videos
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
01:22Heart Failure Drugs: β-Blockers
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
01:17Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...